YBX1 and breast carcinoma: Having demonstrated that YB-1 can transactivate EGFR we next determined whether YB-1 interacted with the EGFR promoter in the basal-like breast cancer cells to further confirm binding observed in breast cancer cell lines that were not basal-like [4], and to address whether this occurs in a manner that is dependent on S102 phoshorylation using a newly developed antibody directed at YB-1(S102) [20].